Episode Details
Back to Episodes
Maze CEO Sells Big Stake, But Why It’s Not Alarming
Description
Jason Coloma, CEO of Maze Therapeutics, sold over 32,000 shares worth nearly $850K in a single transaction — the largest sale since last May — amid strong stock gains of over 160% in the past year. Though the move sparked investor curiosity, it was executed under a pre-arranged trading plan to avoid insider trading concerns, not as a warning about the company. Coloma still holds nearly 400K shares via trusts. Meanwhile, Maze continues advancing its precision medicine programs with Phase 2 trials expected later this year and over $360M in cash to fund operations through 2029.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/540e2e2d25e5b3ec